Premium
FGF ‐23 is associated with cardiac troponin T and mortality in hemodialysis patients
Author(s) -
Holden Rachel M.,
Beseau David,
Booth Sarah L.,
Adams Michael A.,
Garland Jocelyn S.,
Morton Ross A.,
Collier Christine P.,
Foley Robert N.
Publication year - 2012
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/j.1542-4758.2011.00630.x
Subject(s) - medicine , fibroblast growth factor 23 , hemodialysis , interquartile range , troponin t , cardiology , dialysis , troponin complex , troponin , troponin i , cohort , endocrinology , calcium , parathyroid hormone , myocardial infarction
Fibroblast growth factor 23 ( FGF ‐23) is elevated in patients with end‐stage kidney disease and has been linked with mortality, vascular calcification, markers of bone turnover, and left ventricular hypertrophy. In this cohort study, we determined the correlates of FGF ‐23 (including cardiac troponin T [ cTNT ]) and determined its association with mortality over 3.5 years of follow‐up in 103 prevalent hemodialysis patients. Mean age was 61.2 (15.5) and the mean dialysis vintage was 4.19 years (4.6). The median (interquartile range) FGF ‐23 was 1259 (491, 2885) RU / mL . Independent predictors (estimate standard error) of log‐transformed FGF ‐23 concentrations included phosphorus (0.75 [0.237], P = 0.002) and cardiac troponin T (1.04 [0.41], P = 0.01). There were 57 deaths. In the fully adjusted model, the significant predictors of mortality included age and albumin. The independent association between FGF ‐23 and cTNT is a novel finding. Whether this relationship supports the possibility that a downstream effect of dysregulated phosphorous homeostasis may be enhanced cardiac remodeling requires further study.